Peripheral B cell abnormalities in patients with systemic lupus erythematosus in quiescent phase: Decreased memory B cells and membrane CD19 expression

Journal of Autoimmunity

Volumn 34, Issue 4, 2010, Pages 426-434

  Korganow, Anne Sophie ^a   Knapp, Anne Marie ^a   Nehme Schuster, Hélène ^b   Soulas Sprauel, Pauline ^a   Poindron, Vincent ^a   Pasquali, Jean Louis ^a   Martin, Thierry ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Centre Anticancereux Paul Strauss   (France)

Author keywords

CD19 expression; Memory B cells; Peripheral B cells; Quiescent lupus patients; Systemic lupus erythematosus (SLE)

Indexed keywords

CD19 ANTIGEN; CD45 ANTIGEN; CHLOROQUINE; HYDROXYCHLOROQUINE; STEROID;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY CELL; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIGENS, CD19; ANTIGENS, CD45; B-LYMPHOCYTES; CASE-CONTROL STUDIES; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEMBRANE PROTEINS; MIDDLE AGED; YOUNG ADULT;

EID: 77952240188     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.11.002     Document Type: Article

References (51)

1. Arbuckle M.R., Mc Clain M.T., Rubertone M.V., Hal Scofield R.H., Dennis G.J., James J.A., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
2. Liossis S., Kovacs B., Denni G., Kammer G.M., Tsokos G.C. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 1996, 98:2549-2557.
3. Flores-Borja F., Kabouridis P.S., Jury E.C., Isenberg D.A., Mageed R.A. Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52:3955-3965.
4. Flores-Borja F., Kabouridis P.S., Jury E.C., Isenberg D.A., Mageed R.A. Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2007, 56:291-302.
5. Sato S., Fujimoto M., Hasegawa M., Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis. Arthritis Rheum 2004, 50:1918-1927.
6. Culton D.A., Nicholas M.W., Bunch D.O., Zhen Q.L., Kepler T.B., Dooley M.A., et al. Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell tolerance loss. J Clin Immunol 2007, 27:53-68.
7. Huck S., Le Corre R., Youinou P., Zouali M. Expression of B cell receptor associated signaling molecules in human lupus. Autoimmunity 2001, 33:213-224.
8. O'Keefe T.L., Williams G.T., Batista F.D. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999, 189:1307-1313.
9. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
10. Reininger L., Winkler T.H., Kalberer C.P., Jourdan M., Melchers F., Rolink A.G. Intrinsic B cell defects in NZB and NZW mice contribute to systemic lupus erythematosus in (NZB × NZW)F1 mice. J Exp Med 1996, 184:853-861.
11. Odendahl M., Jacobi A., Hansen A., Feist E., Hiepe F., Burmester G.P., et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000, 165:5970-5979.
12. Jacobi A.M., Odendahl M., Reiter K., Bruns A., Burmester G., Radbruch A. Correlation between circulating CD27 high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:1332-1342.
13. Chang N.H., Mc Kenzie T., Bonventi G., Landolt-Marticorena, Fortin P.R., Gladman D., et al. Expanded population of activated antigen-engaged cells within the naïve B cell compartment of patients with systemic lupus erythematosus. J Immunol 2008, 180:1276-1284.
14. Jacobi A.M., Reiter K., Mackay M., Aranow C., Hiepe F., Radbruch A., et al. Activated memory B cell subsets correlate with disease activity in systemic lupus. Arthritis Rheum 2008, 58:1762-1773.
15. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
16. Liang M.H., Socher S.A., Larson M.G., Schur P.H. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus. Arthritis Rheum 1989, 32:1107-1118.
17. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Derivation of the SLEDAI. A disease activity index for SLE patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35:630-640.
18. Soulas P., Woods A., Jaulhac B., Knapp A.M., Pasquali J.L., Martin T., et al. Autoantigen, innate immunity and T cells cooperate to break B cell tolerance during bacterial infection. J Clin Invest 2005, 115:2257-2267.
19. Arce E., Jackson D.G., Gill M.A., Bennett L.B., Banchereau J., Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 2001, 167:2361-2369.
20. Wehr C., Eibel H., Masilamani M., Illges H., Schlesier M., Peter H.H., et al. A new CD21low B cell population in the peripheral blood of patients with SLE. Clin Immunol 2004, 113:161-171.
21. Wei C., Anolik J., Cappione A., Zheng B., Pugh-Bernard A., Brooks J., et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007, 178:6624-6633.
22. Desai-Mehta A., Lu L., Ramsey-Goldman R., Datta S.K. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996, 97:2063-2073.
23. Bijl M., Horst G., Limburg P.C., Kallenberg C.G. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis 2001, 60:523-526.
24. Grammer A.C., Lipsky P.E. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum 2002, 46:1417-1429.
25. Koarada S., Tada Y., Ushiyama O., Morito F., Suzuki N., Ohta A., et al. B cells lacking RP105, a novel B cell antigen, in systemic lupus erythematosus. Arthritis Rheum 1999, 42:2593-2600.
26. Kikuchi Y., Koarada S., Tada Y., Ushiyama O., Morito F., Suzuki N., et al. RP105-lacking B cells from SLE patients are responsible for the production of immunoglobulins and autoantibodies. Arthritis Rheum 2002, 46:3259-3265.
27. Matsumoto A.K., Martin D.R., Carter R.H., Klickstein L.B., Ahearn J.M., Fearon D.T. Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J Exp Med 1993, 178:1407-1417.
28. Maecker H.T., Levy S. Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J Exp Med 1997, 185:1505-1510.
29. Shoham T., Rajapaksa R., Boucheix C., Rubinstein E., Poe J.C., Tedder T.F., et al. The tetraspanin CD81 regulates the expression of CD19 during B cell development in a postendoplasmic reticulum compartment. J Immunol 2003, 171:4062-4072.
30. Van Zelm M.C., Reisli I., van der Burg M., Castano D., van Noesel C.J.M., van Tol M.J.D., et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006, 354:1901-1912.
31. Hermiston M.L., Tan A.L., Gupta V.A., Majeti R., Weiss A. The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity 2005, 23:635-647.
32. Cyster J.G., Healy J.I., Kishihara K., Mak T.W., Thomas M.L., Goodnow C.C. Regulation of B-lymphocyte negative and positive selection by tyrosine phosphatase CD45. Nature 1996, 381:325-328.
33. Sanz I., Chungwen W., Eun-Hyung L., Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008, 20:67-82.
34. Hoyer B.F., Moser K., Hauser A.E., Peddinghaus A., Voigt C., Eilat D., et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004, 7:1577-1584.
35. Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004, 50:3580-3590.
36. Anolik J.H., Barnard J., Owen T., Zheng B., Kemshetti S., Looney R.J., et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007, 56:3044-3056.
37. Sato S., Hasegawa M., Fujimoto M., Tedder T.F., Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000, 165:6635-6643.
38. Carter R.H., Fearon D.T. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992, 3:105-107.
39. Fujimoto M., Fujimoto Y., Poe J.C., Jansen P.J., Lowell C.A., DeFranco A.L., et al. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 2000, 13:47-57.
40. Kurosaki T., Hikida M. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev 2009, 228:132-148.
41. Engel P., Zhou L.J., Ord D.C., Sato S., Koller B., Tedder T.F. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 1995, 3:39-50.
42. Nutt S.L., Heavey B., Rolink A.G., Busslinger M. Commitment of the B-lymphoid lineage depends on the transcription factor Pax 5. Nature 1999, 401:556-562.
43. Kuroki K., Tschuchiya N., Tsao B.P., Grossman J.M., Fukazawa T., Hagiwara K., et al. Polymorphisms of human CD19 gene: possible association with susceptibility to systemic lupus erythematosus in Japanese. Genes Immun 2002, (Suppl. 1):S21-S30.
44. Nicholas M.W., Dooley M.A., Hogan S.L., Anolik J., Looney J., Sanz I., et al. A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. Clin Immunol 2008, 126:189-201.
45. Hase H., Kanno Y., Kojima M., Hasegawa K., Sakurai D., Kojima H., et al. BAFF/BlyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood 2004, 103:2257-2265.
46. Carter R.H., Zhao H., Liu X., Pelletier M., Chatham W., Kimberly R., et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005, 52:3943-3954.
47. Petri M., Stohl W., Chatham W., Mc Cune W.J., Chevrier M., Ryel J., et al. Association of plasma B lymphocyte stimulator levels and diseases activity in systemic lupus erythematosus. Arthritis Rheum 2008, 58:2453-2459.
48. Doreau A., Belot A., Bastid J., Riche B., Trescol-Biemont M.C., Ranchin B., et al. Interleukin 17 acts in synergy with B-cell activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009, 10:778-785.
49. Chu V.T., Enghard P., Schürer S., Steinhauser G., Rudolph B., Riemekasten G., et al. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 2009, 60:2083-2093.
50. Binard A., Le Pottier L., Saraux A., Devauchelle-Pensec V., Pers J.A., Youinou P. Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?. J Autoimmun 2008, 30:1-4.
51. Stohl W., Metyas S., Tan S.M., Cheema G.S., Oamar B., Xu D., et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003, 48:3475-3486.